Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ORGO 
Organogenesis Holdings Inc (ORGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: ORGO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.6% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 657.40M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 4 | Beta 1.49 | 52 Weeks Range 2.61 - 7.08 | Updated Date 11/30/2025 |
52 Weeks Range 2.61 - 7.08 | Updated Date 11/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When - | Estimate 0.0629 | Actual 0.1775 |
Profitability
Profit Margin 0.22% | Operating Margin (TTM) 14.69% |
Management Effectiveness
Return on Assets (TTM) 0.18% | Return on Equity (TTM) 0.3% |
Valuation
Trailing PE - | Forward PE 12.32 | Enterprise Value 765320895 | Price to Sales(TTM) 1.41 |
Enterprise Value 765320895 | Price to Sales(TTM) 1.41 | ||
Enterprise Value to Revenue 1.65 | Enterprise Value to EBITDA 198.16 | Shares Outstanding 126912142 | Shares Floating 55700470 |
Shares Outstanding 126912142 | Shares Floating 55700470 | ||
Percent Insiders 46.69 | Percent Institutions 54.67 |
Upturn AI SWOT
Organogenesis Holdings Inc
Company Overview
History and Background
Organogenesis Holdings Inc. was founded in 1985. It has evolved from developing cell-based therapies to focusing on wound care and regenerative medicine. It went public via a SPAC in 2018.
Core Business Areas
- Advanced Wound Care: Focuses on providing a portfolio of wound care products, including bioengineered and regenerative medicine products.
- Surgical & Sports Medicine: Develops and commercializes products for use in surgical and sports medicine procedures, focusing on tissue repair and regeneration.
Leadership and Structure
The company is led by a board of directors and a management team headed by the CEO. The structure includes departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Apligraf: A bioengineered skin substitute used to treat diabetic foot ulcers and venous leg ulcers. Competitors include Integra LifeSciences (IART) and Mimedx (MDXG). Revenue figures are not available publicly without specialized sources.
- Dermagraft: A cryopreserved human fibroblast-derived dermal substitute for treating diabetic foot ulcers. Competitors include Integra LifeSciences (IART) and Mimedx (MDXG). Revenue figures are not available publicly without specialized sources.
- PuraPly AM: An antimicrobial barrier used to manage wounds with varying levels of exudate. Competitors include Convatec (CTEC) and Smith & Nephew (SNN). Revenue figures are not available publicly without specialized sources.
Market Dynamics
Industry Overview
The advanced wound care market is growing due to the increasing prevalence of chronic wounds (e.g., diabetic ulcers, pressure ulcers). The regenerative medicine sector is also expanding due to advancements in tissue engineering and cell therapies.
Positioning
Organogenesis is positioned as a leader in bioengineered wound care products. Its competitive advantages include its established product portfolio and focus on regenerative medicine.
Total Addressable Market (TAM)
The global advanced wound care market is estimated to be in the tens of billions of USD, and the regenerative medicine market is similarly sized and growing. Organogenesis is well positioned to serve a substantial portion of this market.
Upturn SWOT Analysis
Strengths
- Established product portfolio
- Strong presence in advanced wound care market
- Focus on regenerative medicine
- Proprietary technologies
Weaknesses
- Reliance on reimbursement approvals
- Competition from larger companies
- Profitability concerns
- Debt Levels
Opportunities
- Expanding into new geographic markets
- Developing new products
- Acquiring complementary businesses
- Increasing awareness of advanced wound care solutions
Threats
- Changes in reimbursement policies
- Increased competition
- Product liability claims
- Economic downturns
Competitors and Market Share
Key Competitors
- IART
- MDXG
- SNN
- CTEC
Competitive Landscape
Organogenesis has a strong position in bioengineered skin substitutes but faces competition from larger companies with broader product portfolios.
Major Acquisitions
NuTech Medical
- Year: 2017
- Acquisition Price (USD millions): 92
- Strategic Rationale: Expanded Organogenesisu2019 portfolio of wound care products and strengthened its market position. Increased access to amnion products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires accessing prior year revenues and computing CAGR.
Future Projections: Analyst estimates are constantly updated and available from financial data providers.
Recent Initiatives: Recent initiatives would involve tracking the company's announcements on product launches, expansions, and collaborations.
Summary
Organogenesis holds a prominent position in the wound care market, particularly with bioengineered skin substitutes. Its financial performance and profitability need close attention. The company faces competition from larger players and must navigate reimbursement complexities while exploring growth opportunities.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry reports
- Company website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market data and analyst opinions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Organogenesis Holdings Inc
Exchange NASDAQ | Headquaters Canton, MA, United States | ||
IPO Launch date 2017-01-05 | President, CEO, Chair of the Board Mr. Gary S. Gillheeney Sr. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 869 | Website https://organogenesis.com |
Full time employees 869 | Website https://organogenesis.com | ||
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.